Human respiratory syncytial virus and other viral infections in infants receiving palivizumab (Q40430519)

20 September 2017

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab (English)

1 reference

respiratory syncytial virus

20 September 2017

object named as

Human respiratory syncytial virus

1 reference

6

Gaston De Serres

1 reference

20 September 2017

1

Guy Boivin

1 reference

20 September 2017

Georges Caouette

2

1 reference

20 September 2017

Line Frenette

series ordinal

3

1 reference

20 September 2017

Julie Carbonneau

series ordinal

4

1 reference

20 September 2017

Manale Ouakki

series ordinal

5

1 reference

20 September 2017

27 February 2008

1 reference

Journal of Clinical Virology

20 September 2017

1 reference

20 September 2017

42

1 reference

20 September 2017

1

1 reference

20 September 2017

52-57

1 reference

Metapneumovirus and acute wheezing in children.

20 September 2017

1 reference

12 December 2020

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

12 December 2020

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

1 reference

12 December 2020

Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children

1 reference

12 December 2020

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

12 December 2020

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

1 reference

12 December 2020

Respiratory syncytial virus infection: clinical features, management, and prophylaxis

1 reference

12 December 2020

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants

1 reference

12 December 2020

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats

1 reference

12 December 2020

In vivo selection of respiratory syncytial viruses resistant to palivizumab

1 reference

12 December 2020

Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease.

1 reference

12 December 2020

Respiratory syncytial virus and other respiratory viruses

1 reference

12 December 2020

Respiratory syncytial virus: the virus, the disease and the immune response

1 reference

12 December 2020

A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Selected populations at increased risk from respiratory syncytial virus infection

1 reference

12 December 2020

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

1 reference

12 December 2020

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants

1 reference

12 December 2020

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

12 December 2020

Human metapneumovirus infections in hospitalized children

1 reference

12 December 2020

10.1016/J.JCV.2007.11.012

Identifiers

DOI

1 reference

20 September 2017

1 reference